02:35 PM EST, 11/13/2025 (MT Newswires) -- Salarius Pharmaceuticals ( SLRX ) completed its merger with Decoy Therapeutics, with the combined entity now operating under the Decoy name and concentrating on peptide conjugate drug development.

Decoy plans to submit a new investigational drug application within a year for its lead pan-coronavirus antiviral candidate and advance additional programs targeting influenza, COVID-19, RSV, and gastrointestinal cancers.

Decoy co-founder Frederick Pierce will be chief executive officer, while other Decoy executives will lead scientific, business, and medical functions, Salarius said Thursday in a statement.

Price: 1.17, Change: +0.02, Percent Change: +1.74